← Back to Clinical Trials
Recruiting NCT05030220

NCT05030220 Testosterone Levels and Cutibacterium

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05030220
Status Recruiting
Phase
Sponsor University of Washington
Condition Arthroplasty, Replacement, Shoulder
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2020-07-01
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 89 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2020-07-01 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Phase 1: In 51 patients undergoing shoulder arthroplasties, total serum testosterone, free testosterone and sex hormone binding globulin levels obtained in the clinic before surgery were correlated with the levels of Cutibacterium on the skin in clinic, in the operating room prior to surgery, and in the skin incision. Phase 2: The investigators wish to determine if preoperative serum testosterone levels are associated with risk for shoulder PJI (periprosthetic joint infection) in patients undergoing primary shoulder arthroplasty. Also to determine if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.

Eligibility Criteria

Phase 1 Inclusion Criteria: * Patients having elective shoulder arthroplasty Phase 1 Exclusion Criteria: * history of shoulder septic arthritis * antibiotic use within 3 months prior to surgery * recent treatment for acne * Lacked fluency in English Phase 2 Inclusion Criteria: * Patients having elective shoulder arthroplasty Phase 2 Exclusion Criteria: * Lacked fluency in English

Contact & Investigator

Central Contact

Jason E Hsu, MD

✉ jehsu@uw.edu

📞 330-883-8829

Principal Investigator

Jason E Hsu, MD

PRINCIPAL INVESTIGATOR

University of Washington

Frequently Asked Questions

Who can join the NCT05030220 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Arthroplasty, Replacement, Shoulder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05030220 currently recruiting?

Yes, NCT05030220 is actively recruiting participants. Contact the research team at jehsu@uw.edu for enrollment information.

Where is the NCT05030220 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT05030220 clinical trial?

NCT05030220 is sponsored by University of Washington. The principal investigator is Jason E Hsu, MD at University of Washington. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology